Targeting cell division protein CDK2 could boost immunotherapy response across a wide range of cancers

New probe from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are presently being tested arsenic treatments that dilatory the maturation of a constrictive scope of cancers, could perchance beryllium much broadly applicable to a wide scope of cancers erstwhile combined with immunotherapy.